Showing 3,181 - 3,200 results of 17,304 for search '"random"', query time: 0.09s Refine Results
  1. 3181
  2. 3182
  3. 3183
  4. 3184
  5. 3185

    Reseña de Libros: GUSINDE HENTSCHEL, Martin; Diarios de viaje de investigación a Tierra del Fuego (1918-1920), Penguin Random House, Santiago de Chile, 2022, 136 pp. Traducción de Marisol Palma Behnke. by Ana Butto

    Published 2024-10-01
    “…Reseña de Libros: GUSINDE HENTSCHEL, Martin; Diarios de viaje de investigación a Tierra del Fuego (1918-1920), Penguin Random House, Santiago de Chile, 2022, 136 pp. Traducción de Marisol Palma Behnke.…”
    Get full text
    Article
  6. 3186
  7. 3187
  8. 3188
  9. 3189
  10. 3190

    Efficacy and safety of glycyrrhizic acid and essential phospholipids (Phosphogliv) combination for alcoholic liver disease: results of the double-blind randomized placebo-controlled multicenter post-registration (phase IV) clinical trial «Jaguar» (PHG-M2/P03-12) by I. G. Bakulin, N. A. Bokhan, P. O. Bogomolov, N. I. Geyvandova, M. V. Matsiyevich, M. A. Vinnikova, V. G. Morozov, O. M. Khromtsova, G. S. Soldatova, O. Yu. Shiryayev, R. D. Ilyuk, K. V. Rybakova, A. G. Katkovskaya, S. V. Teplykh, A. A. Bagretsova, M. V. Krasnova, Ye. V. Alekseyeva, A. V. Anipchenko, Ye. V. Baskakov

    Published 2018-08-01
    “…The original study included overall 120 patients with ALD, who were randomized in two identical groups. The patients of the main group (group A) received 2 courses of therapy: the first - Phosphogliv 5 mg/day as intravenous bolus injection for 2 wks, followed by the oral intake of 2 capsules t.i.d. for 10 wks (the total treatment duration was 24 wks). …”
    Get full text
    Article
  11. 3191
  12. 3192

    The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study by Yin Yin, Min Jia, Yufeng Li, Wei Zhao, Shuhong Chen, Peiyuan Huo, Qinghua Zhao, Lan Yu, Cha Wang, Yirui Ma, Meixia Wang, Jing Zhang

    Published 2025-01-01
    “…This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone. Method: This randomized, double-blind, parallel-controlled Phase Ib clinical study was conducted in healthy Chinese population to evaluate the safety, pharmacokinetics, and neutralizing activity of rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines, and to compare the neutralizing activity of rhRIG + vaccine with that of HRIG + vaccine and vaccine alone. 72 healthy participants divided into 6 groups of 12 individuals. …”
    Get full text
    Article
  13. 3193
  14. 3194

    Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis by Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong

    Published 2025-12-01
    “…Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).Methods In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. …”
    Get full text
    Article
  15. 3195
  16. 3196
  17. 3197
  18. 3198
  19. 3199
  20. 3200